Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain

(Paris, France – 10 September 2024) – Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI^® is now available for patients with prostate cancer. PYLCLARI^® (INN: Piflufolastat (¹⁸F) also known as (¹⁸F)-DCFPyL) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:

• Primary staging of patients with high-risk prostate cancer prior to initial curative therapy
• To localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent

Benoit Woessmer, PET Europe CEO at Curium commented, “The availability of PYLCLARI^® in Spain is an important milestone for patients with prostate cancer and underscores our dedication to improving the choice of diagnostic PET radiopharmaceuticals. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are proud that the availability of PYLCLARI^® continues to grow and now covers seven countries including Austria, France, Germany, Greece, Italy, the Netherlands, and Spain.”

In Spain, prostate cancer is one of the most common cancers among men with around 30,000 new cases diagnosed nationwide every year. PYLCLARI^® is being produced by Curium at two sites in Madrid and one site in Sevilla, ensuring timely and efficient distribution across the country.

For more information about PYLCLARI^®: www.pylclari.com
In the U.S., Lantheus received approval for PYLARIFY^® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.